Smark Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 36 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 0.32 M
About Smark Pharmaceuticals
Smark Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 October 1988 and has a history of 36 years and three months. Its registered office is in Kanpur Nagar, Uttar Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹0.32 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Arun Sharma and Ankit Sharma serve as directors at the Company.
Company Details
-
Location
Kanpur Nagar, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U85110UP1988PTC010158
-
Company No.
010158
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
27 Oct 1988
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Smark Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Sharma
|
Director | 27-Oct-1988 | Current |
|
Ankit Sharma
|
Director | 21-Aug-2018 | Current |
Financial Performance of Smark Pharmaceuticals.
Smark Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Smark Pharmaceuticals?
In 2017, Smark Pharmaceuticals had a promoter holding of 50.00% and a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹0.32 M
Charges Breakdown by Lending Institutions
- Bank Of Baroda : 0.02 Cr
- State Bank Of India : 0.01 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Nov 2007 | Bank Of Baroda | ₹0.20 M | Satisfied |
| 13 Dec 1991 | State Bank Of India | ₹0.12 M | Satisfied |
How Many Employees Work at Smark Pharmaceuticals?
Unlock and access historical data on people associated with Smark Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Smark Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Smark Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
